Cipher Pharmaceuticals (PHE) Stock Overview
Operates as a specialty pharmaceutical company in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
PHE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Cipher Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$7.60 |
| 52 Week High | CA$10.40 |
| 52 Week Low | CA$6.85 |
| Beta | 0.85 |
| 1 Month Change | -16.48% |
| 3 Month Change | -4.40% |
| 1 Year Change | -8.98% |
| 3 Year Change | 194.00% |
| 5 Year Change | 1,179.46% |
| Change since IPO | 187.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHE | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.3% | -1.9% | 1.6% |
| 1Y | -9.0% | 21.6% | 7.9% |
Return vs Industry: PHE underperformed the German Pharmaceuticals industry which returned 23.6% over the past year.
Return vs Market: PHE underperformed the German Market which returned 7.3% over the past year.
Price Volatility
| PHE volatility | |
|---|---|
| PHE Average Weekly Movement | 13.1% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 13.9% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: PHE's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: PHE's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Craig Mull | www.cipherpharma.com |
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company’s licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults.
Cipher Pharmaceuticals Inc. Fundamentals Summary
| PHE fundamental statistics | |
|---|---|
| Market cap | €228.41m |
| Earnings (TTM) | €14.73m |
| Revenue (TTM) | €42.47m |
Is PHE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHE income statement (TTM) | |
|---|---|
| Revenue | US$50.06m |
| Cost of Revenue | US$12.85m |
| Gross Profit | US$37.20m |
| Other Expenses | US$19.84m |
| Earnings | US$17.36m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.69 |
| Gross Margin | 74.32% |
| Net Profit Margin | 34.69% |
| Debt/Equity Ratio | 11.4% |
How did PHE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/20 19:54 |
| End of Day Share Price | 2026/02/20 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cipher Pharmaceuticals Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Novak | ATB Cormark Historical (Cormark Securities) |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Prakash Gowd | CIBC Capital Markets |